Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 1997, for Aastrom Biosciences, Inc. (Note: The input metadata referenced "Vericel Corp," but the filing text explicitly identifies the registrant as Aastrom Biosciences, Inc.). The company is in the development stage, focusing on research and product development for ex vivo production of human stem cells and hematopoietic tissues. It has not yet generated revenue from product sales and does not anticipate profitability for at least the next several years.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 1997 | Three Months Ended Sep 30, 1996 |
|---|---|---|
| Total Revenues | $16,000 | $224,000 |
| Total Costs and Expenses | $3,856,000 | $3,612,000 |
| Net Loss | $(3,625,000) | $(3,273,000) |
| Net Loss Per Share | $(0.27) | $(0.32) |
| Cash and Cash Equivalents (Sep 30, 1997) | $1,505,000 | N/A |
| Short-term Investments (Sep 30, 1997) | $12,126,000 | N/A |
| Total Liquid Assets | $13,631,000 | N/A |
| Accumulated Deficit (Inception to Sep 30, 1997) | $(44,938,000) | N/A |
| Current Liabilities | $1,820,000 | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues dropped significantly from $224,000 in the prior year quarter to $16,000. The 1996 revenue was primarily driven by a research collaboration with Rhone-Poulenc Rorer, Inc., which concluded in September 1996.
- Expense Increase: Total costs and expenses rose to $3,856,000 from $3,612,000. This was driven by an increase in Research and Development (R&D) expenses to $3,243,000 and General and Administrative (G&A) expenses to $613,000.
- Widened Net Loss: The net loss increased to $3,625,000 from $3,273,000 due to the combination of lower revenues and higher operating expenses.
- Liquidity Position: Combined cash, cash equivalents, and short-term investments decreased by $3,376,000 from June 30, 1997, to September 30, 1997. This reduction was primarily used to finance operations ($3,331,000), capital equipment additions ($44,000), and debt payments ($42,000).
Guidance, Outlook, and Risks
- Outlook: Management does not expect to generate positive cash flows from operations for at least the next several years. Future revenue sources are expected to be limited to grants, research funding, and milestone payments until product sales commence.
- Funding Needs: The company intends to seek additional funding through collaborative arrangements, grants, or public/private financing. There is no assurance that such funding will be available on acceptable terms.
- Key Risks:
- Regulatory Approval: Success depends on FDA and foreign regulatory approvals for the Aastrom Cell Production System (CPS). Pre-pivotal clinical trials are ongoing, with risks of patient complications or death noted.
- Commercialization: A strategic alliance with Cobe BCT, Inc. handles distribution, but Cobe may terminate the agreement if commercialization by December 31, 1998, is deemed unlikely.
- Supply Chain: Reliance on third-party manufacturers for key components (cytokines, serum) creates supply risk.
- Contractual Obligations: The company has annual renewal fees of $1,000,000 payable to Immunex for the next three fiscal years.
Investor Verification Checklist
- Verify the status and results of the ongoing pre-pivotal clinical trials for the Aastrom CPS.
- Confirm the terms and stability of the distribution agreement with Cobe BCT, Inc., specifically the termination clauses.
- Assess the sufficiency of current liquid assets ($13.6M) to fund operations until the next anticipated financing event.
- Review the timeline for potential FDA clearance to commence pivotal clinical trials.
- Monitor the company's ability to secure the $1,000,000 annual renewal fees payable to Immunex.